Senhwa Biosciences has partnered with a global investment group to accelerate its AI-related drug development. The company received $16 million from GEM to advance its clinical pipeline and AI-driven drug discovery platform. Senhwa is focusing on oncology programs and using AI technology to identify combination cancer therapies quickly, positioning itself as a leader in the immuno-oncology 2.0 field.

Leave a Reply